Recent Company News

• 10:01 AM ET Sep 14, 2026
  

  Transcript Intelligence: Pharming Group at H.C. Wainwright Global Investment Conference

• 02:02 PM ET Sep 11, 2026
  

  Follow-up: Pharming confirms FDA approval of Joenja as first treatment for children with APDS in the U.S. (€0.93, 0.00)

• 12:13 PM ET Sep 11, 2026
  

  FDA approves Pharming Group's Joenja (leniolisib) for the treatment of children aged 4-11 years with activated phosphoinositide 3-kinase delta syndrome (€0.93, 0.00)

• 01:01 PM ET Aug 16, 2026
  

  Bronstein, Gewirtz & Grossman, LLC Is Investigating Pharming Group N.V. (PHAR) And Encourages Shareholders to Connect

• 01:01 PM ET Aug 13, 2026
  

  Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pharming Group N.V. (PHAR) and Encourages Shareholders to Learn More About the Investigation

• 04:53 AM ET Aug 13, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:56 AM ET Aug 13, 2026
  

  StreetAccount Summary - European pre-market trading update

• 01:07 AM ET Aug 13, 2026
  

  Pharming Group announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with activated PI3K delta syndrome (APDS) aged 4 years and older (€1.00, 0.00)

• 12:59 PM ET Aug 12, 2026
  

  Pharming Group N.V. (PHAR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

• 01:01 PM ET Aug 11, 2026
  

  Pharming Group N.V. (PHAR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation